Rational design of multifunctional magnetic mesoporous silica nanoparticle for tumor-targeted magnetic resonance imaging and precise therapy

Biomaterials

Volumn 76, Issue , 2016, Pages 87-101

  Chen, Wei Hai ^a   Luo, Guo Feng ^a   Lei, Qi ^a   Cao, Feng Yi ^a   Fan, Jin Xuan ^a   Qiu, Wen Xiu ^a   Jia, Hui Zhen ^a   Hong, Sheng ^a   Fang, Fang ^b   Zeng, Xuan ^a   Zhuo, Ren Xi ^a   Zhang, Xian Zheng ^a  

^a WUHAN UNIVERSITY   (China)

^b Chinese Academy of Sciences   (China)

Author keywords

Magnetic resonance imaging; Mesoporous silica nanoparticle; Precise therapy; Theranostic; Tumor targeted

Indexed keywords

CELLS; DISEASES; DRUG INTERACTIONS; ENZYME ACTIVITY; MAGNETIC FIELD EFFECTS; MAGNETIC RESONANCE IMAGING; MAGNETISM; MESOPOROUS MATERIALS; MOLECULAR BIOLOGY; NANOPARTICLES; PLATINUM; RECONFIGURABLE HARDWARE; SILICA; TUMORS;

BETA-CYCLODEXTRIN; EXTERNAL MAGNETIC FIELD; HOST GUEST INTERACTIONS; MAGNETIC MESOPOROUS SILICAS; MESOPOROUS SILICA; MESOPOROUS SILICA NANOPARTICLES; PRECISE THERAPY; THERANOSTIC;

NANOMAGNETICS;

ARGINYLGLYCYLASPARTIC ACID; BETA CYCLODEXTRIN; CISPLATIN; DOXORUBICIN; MESOPOROUS SILICA NANOPARTICLE; MULTIFUNCTIONAL THERANOSTIC MAGNETIC MESOPOROUS SILICA NANOPARTICLE; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; NANOPARTICLE; SILICON DIOXIDE;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ATOMIC EMISSION SPECTROMETRY; CANCER CELL; CANCER INHIBITION; CANCER LOCALIZATION; CANCER THERAPY; CARBON NUCLEAR MAGNETIC RESONANCE; CELL VIABILITY; CELLULAR DISTRIBUTION; CONFOCAL LASER MICROSCOPY; COS 7 CELL LINE; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG SYNTHESIS; EARLY DIAGNOSIS; FEMALE; HISTOCHEMISTRY; HUMAN; HUMAN CELL; IN VITRO STUDY; INFRARED SPECTROSCOPY; MAGNETIC FIELD; MOLECULAR WEIGHT; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SOLID; SURFACE AREA; SURFACE PROPERTY; TRANSMISSION ELECTRON MICROSCOPY; TUMOR MICROENVIRONMENT; TUMOR VOLUME; UTERINE CERVIX CARCINOMA; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; CHLOROCEBUS AETHIOPS; COS 1 CELL LINE; HELA CELL LINE; NEOPLASMS; PATHOLOGY; PROCEDURES; THERANOSTIC NANOMEDICINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CERCOPITHECUS AETHIOPS; COS CELLS; DOXORUBICIN; HELA CELLS; HUMANS; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED BALB C; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; NEOPLASMS; SILICON DIOXIDE; THERANOSTIC NANOMEDICINE;

EID: 84958151962     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.10.053     Document Type: Article

References (53)

1. Peer D., Karp J.M., Hong S., Farokhzad O.C., Margalit R., Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2007, 2:751-760.
2. Wang A.Z., Langer R., Farokhzad O.C. Nanoparticle delivery of cancer drugs. Annu. Rev. Med. 2012, 63:185-198.
3. Koo H., Huh M.S., Sun I.C., Yuk S.H., Choi K., Kim K., et al. In vivo targeted delivery of nanoparticles for theranosis. Acc. Chem. Res. 2011, 44:1018-1028.
4. 4 Core@hybrid@Au shell nanocomposite for bimodal imaging and photothermal therapy. Adv. Mater. 2011, 23:5392-5397.
5. Meng H., Xue M., Xia T., Ji Z., Tarn D.Y., Zink J.I., et al. Use of size and a copolymer design feature to improve the biodistribution and the enhanced permeability and retention effect of doxorubicin-loaded mesoporous silica nanoparticles in a murine xenograft tumor model. ACS Nano 2011, 5:4131-4144.
6. Peng Z.H., Kopeček J. Enhancing accumulation and penetration of HPMA copolymer-doxorubicin conjugates in 2D and 3D prostate cancer cells via iRGD conjugation with an MMP-2 cleavable spacer. J. Am. Chem. Soc. 2015, 137:6726-6729.
7. Ling D., Park W., Park S.J., Lu Y., Kim K.S., Hackett M.J., et al. Multifunctional tumor pH-sensitive self-assembled nanoparticles for bimodal imaging and treatment of resistant heterogeneous tumors. J. Am. Chem. Soc. 2014, 136:5647-5655.
8. Du J.Z., Du X.J., Mao C.Q., Wang J. Tailor-made dual pH-sensitive polymer-doxorubicin nanoparticles for efficient anticancer drug delivery. J. Am. Chem. Soc. 2011, 133:17560-17563.
9. Chen W.H., Luo G.F., Lei Q., Jia H.Z., Hong S., Wang Q.R., et al. MMP-2 responsive polymeric micelles for cancer-targeted intracellular drug delivery. Chem. Commun. 2015, 51:465-468.
10. Wang H., Wu Y., Zhao R., Nie G. Engineering the assemblies of biomaterial nanocarriers for delivery of multiple theranostic agents with enhanced antitumor efficacy. Adv. Mater. 2013, 25:1616-1622.
11. Zhang J., Yuan Z.F., Wang Y., Chen W.H., Luo G.F., Cheng S.X., et al. Multifunctional envelope-type mesoporous silica nanoparticles for tumor-triggered targeting drug delivery. J. Am. Chem. Soc. 2013, 135:5068-5073.
12. 2 nanoparticles: a targeted theranostic platform for magnetic resonance imaging and photoacoustic tomography-guided photothermal therapy. Adv. Mater. 2014, 26:4114-4120.
13. Vivero-Escoto J.L., Slowing I.I., Trewyn B.G., Lin V.S. Mesoporous silica nanoparticles for intracellular controlled drug delivery. Small 2010, 6:1952-1967.
14. Ambrogio M.W., Thomas C.R., Zhao Y.L., Zink J.I., Stoddart J.F. Mechanized silica nanoparticles: a new frontier in theranostic nanomedicine. Acc. Chem. Res. 2011, 44:903-913.
15. He Q., Shi J. MSN anti-cancer nanomedicines: chemotherapy enhancement, overcoming of drug resistance, and metastasis inhibition. Adv. Mater. 2014, 26:391-411.
16. Tang F., Li L., Chen D. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv. Mater. 2012, 24:1504-1534.
17. Nguyen T.D., Tseng H.R., Celestre P.C., Flood A.H., Liu Y., Stoddart J.F., et al. A reversible molecular valve. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:10029-10034.
18. Zhang Q., Liu F., Nguyen K.T., Ma X., Wang X.J., Xing B.G., et al. Multifunctional mesoporous silica nanoparticles for cancer-targeted and controlled drug delivery. Adv. Funct. Mater. 2012, 22:5144-5156.
19. Luo Z., Cai K., Hu Y., Zhang B., Xu D. Cell-specific intracellular anticancer drug delivery from mesoporous silica nanoparticles with pH sensitivity. Adv. Healthc. Mater. 2012, 1:321-325.
20. Kim H., Kim S., Park C., Lee H., Park H.J., Kim C. Glutathione-induced intracellular release of guests from mesoporous silica nanocontainers with cyclodextrin gatekeepers. Adv. Mater. 2010, 22:4280-4283.
21. Patel K., Angelos S., Dichtel W.R., Coskun A., Yang Y.W., Zink J.I., et al. Enzyme-responsive snap-top covered silica nanocontainers. J. Am. Chem. Soc. 2008, 130:2382-2383.
22. Luo Z., Ding X., Hu Y., Wu S., Xiang Y., Zeng Y., et al. Engineering a hollow nanocontainer platform with multifunctional molecular machines for tumor-targeted therapy in vitro and in vivo. ACS Nano 2013, 7:10271-10284.
23. Chen C., Geng J., Pu F., Yang X., Ren J., Qu X. Polyvalent nucleic acid/mesoporous silica nanoparticle conjugates: dual stimuli-responsive vehicles for intracellular drug delivery. Angew. Chem. Int. Ed. Engl. 2011, 50:882-886.
24. Kim J., Lee J.E., Lee J., Yu J.H., Kim B.C., An K., et al. Magnetic fluorescent delivery vehicle using uniform mesoporous silica spheres embedded with monodisperse magnetic and semiconductor nanocrystals. J. Am. Chem. Soc. 2006, 128:688-689.
25. Zhao W., Gu J., Zhang L., Chen H., Shi J. Fabrication of uniform magnetic nanocomposite spheres with a magnetic core/mesoporous silica shell structure. J. Am. Chem. Soc. 2005, 127:8916-8917.
26. Nooney R.I., Thirunavukkarasu D., Chen Y., Josephs R., Ostafin A.E. Self-assembly of mesoporous nanoscale silica/gold composites. Langmuir 2003, 19:7628-7637.
27. Liong M., France B., Bradley K.A., Zink J.I. Antimicrobial activity of silver nanocrystals encapsulated in mesoporous silica nanoparticles. Adv. Mater. 2009, 21:1684-1689.
28. Wang Y., Gu H. Core-shell-type magnetic mesoporous silica nanocomposites for bioimaging and therapeutic agent delivery. Adv. Mater. 2015, 27:576-585.
29. Liong M., Lu J., Kovochich M., Xia T., Ruehm S.G., Nel A.E., et al. Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano 2008, 2:889-896.
30. Li Z., Dong K., Huang S., Ju E., Liu Z., Yin M., et al. A smart nanoassembly for multistage targeted drug delivery and magnetic resonance imaging. Adv. Funct. Mater. 2014, 24:3612-3620.
31. 4-Au core-shell nanotrisoctahedra for magnetically targeted and near-infrared light-responsive theranostic platform. J. Am. Chem. Soc. 2014, 136:10062-10075.
32. Yang P., Quan Z., Hou Z., Li C., Kang X., Cheng Z., et al. A magnetic, luminescent and mesoporous core-shell structured composite material as drug carrier. Biomaterials 2009, 30:4786-4795.
33. Kim J., Kim H.S., Lee N., Kim T., Kim H., Yu T., et al. Multifunctional uniform nanoparticles composed of a magnetite nanocrystal core and a mesoporous silica shell for magnetic resonance and fluorescence imaging and for drug delivery. Angew. Chem. Int. Ed. Engl. 2008, 47:8438-8441.
34. Li Z., Yin S., Cheng L., Yang K., Li Y., Liu Z. Magnetic targeting enhanced theranostic strategy based on multimodal imaging for selective ablation of cancer. Adv. Funct. Mater. 2014, 24:2312-2321.
35. Wang C., Xu H., Liang C., Liu Y., Li Z., Yang G., et al. Iron oxide @polypyrrole nanoparticles as a multifunctional drug carrier for remotely controlled cancer therapy with synergistic antitumor effect. ACS Nano 2013, 7:6782-6795.
36. 4@polydopamine core-shell nanocomposites for intracellular mRNA detection and imaging-guided photothermal therapy. ACS Nano 2014, 8:3876-3883.
37. Ling D., Lee N., Hyeon T. Chemical synthesis and assembly of uniformly sized iron oxide nanoparticles for medical applications. Acc. Chem. Res. 2015, 48:1276-1285.
38. Chen Y., Chen H., Zhang S., Chen F., Zhang L., Zhang J., et al. Multifunctional mesoporous nanoellipsoids for biological bimodal imaging and magnetically targeted delivery of anticancer drugs. Adv. Funct. Mater. 2011, 21:270-278.
39. Yuan Y., Kwok R.T., Tang B.Z., Liu B. Targeted theranostic platinum(IV) prodrug with a built-in aggregation-induced emission light-up apoptosis sensor for noninvasive early evaluation of its therapeutic responses in situ. J. Am. Chem. Soc. 2014, 136:2546-2554.
40. Kumar A., Huo S., Zhang X., Liu J., Tan A., Li S., et al. Neuropilin-1-targeted gold nanoparticles enhance therapeutic efficacy of platinum(IV) drug for prostate cancer treatment. ACS Nano 2014, 8:4205-4220.
41. Pan L., Liu J., He Q., Shi J. MSN-mediated sequential vascular-to-cell nuclear-targeted drug delivery for efficient tumor regression. Adv. Mater. 2014, 26:6742-6748.
42. Haubner R., Wester H.J., Weber W.A., Mang C., Ziegler S.I., Goodman S.L., et al. Noninvasive imaging of αvβ3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res. 2001, 61:1781-1785.
43. Luo G.F., Xu X.D., Zhang J., Yang J., Gong Y.H., Lei Q., et al. Encapsulation of an adamantane-doxorubicin prodrug in pH-responsive polysaccharide capsules for controlled release. ACS Appl. Mater. Interfaces 2012, 4:5317-5324.
44. Chen W.H., Xu X.D., Luo G.F., Jia H.Z., Lei Q., Cheng S.X., et al. Dual-targeting pro-apoptotic peptide for programmed cancer cell death via specific mitochondria damage. Sci. Rep. 2013, 3:3468.
45. Deng Y., Qi D., Deng C., Zhang X., Zhao D. Superparamagnetic high-magnetization microspheres with an Fe3O4@SiO2 core and perpendicularly aligned mesoporous SiO2 shell for removal of microcystins. J. Am. Chem. Soc. 2008, 130:28-29.
46. Graf N., Lippard S.J. Redox activation of metal-based prodrugs as a strategy for drug delivery. Adv. Drug Deliv. Rev. 2012, 64:993-1004.
47. Yuan Y., Chen Y., Tang B.Z., Liu B. A targeted theranostic platinum(IV) prodrug containing a luminogen with aggregation-induced emission (AIE) characteristics for in situ monitoring of drug activation. Chem. Commun. 2014, 50:3868-3870.
48. McCarthy J.R., Weissleder R. Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv. Drug Deliv. Rev. 2008, 60:1241-1251.
49. Zitzmann S., Ehemann V., Schwab M. Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res. 2002, 62:5139-5143.
50. Kaneshiro T.L., Lu Z.R. Targeted intracellular codelivery of chemotherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier. Biomaterials 2009, 30:5660-5666.
51. Chen W.H., Lei Q., Luo G.F., Jia H.Z., Hong S., Liu Y.X., et al. Rational design of multifunctional gold nanoparticles via host-guest interaction for cancer-targeted therapy. ACS Appl. Mater. Interfaces 2015, 7:17171-17180.
52. Kalaria D.R., Sharma G., Beniwal V., Ravi Kumar M.N. Design of biodegradable nanoparticles for oral delivery of doxorubicin: in vivo pharmacokinetics and toxicity studies in rats. Pharm. Res. 2009, 26:492-501.
53. Gokcimen A., Cim A., Tola H.T., Bayram D., Kocak A., Ozgüner F., et al. Protective effect of N-acetylcysteine, caffeic acid and vitamin E on doxorubicin hepatotoxicity. Hum. Exp. Toxicol. 2007, 26:519-525.